SU4313 is primarily utilized in research settings as a potent inhibitor of vascular endothelial growth factor receptor (VEGFR) and platelet-derived growth factor receptor (PDGFR). Its application is significant in studying angiogenesis and tumor growth, as it helps in understanding the mechanisms of these receptors in cellular signaling pathways. Researchers employ SU4313 to explore potential therapeutic strategies for cancer, particularly in inhibiting the growth of blood vessels that supply tumors. Additionally, it is used in laboratory experiments to investigate the role of VEGFR and PDGFR in various physiological and pathological processes, providing insights into the development of targeted treatments for diseases involving abnormal cell proliferation and vascularization.